GHRP-2 Dosage, half-life & reference guide

Week by week.

What to expect in the first 8 weeks

1. Day 1–14Community

   Hits harder than Ipamorelin

   Commonly reported: GHRP-2 hits harder than Ipamorelin, with deeper sleep, more noticeable recovery and hunger after a dose (less than GHRP-6). The trade-off: each dose also raises cortisol and prolactin.

   The science

   GHRP-2 (Pralmorelin) is a more potent ghrelin receptor agonist than Ipamorelin but with less selectivity — it elevates cortisol and prolactin in addition to GH. A single dose raised ACTH and cortisol about as much as a CRH stimulation test (Arvat 1997), and in lean men it raised buffet food intake by 36% (Laferrere 2005). Phase II data showed robust GH release curves. Approved in Japan as Pralmorelin for GH deficiency diagnosis.

   Sources

   • Arvat et al. (1997)
   • Laferrere et al. (2005)

   Updated Sep 2026

2. Day 14–56Community

   Recovery and growth are accelerating

   Commonly reported in weeks 2 to 8: faster recovery, better sleep and quicker body-composition changes than with milder secretagogues. If the hunger is manageable and the cortisol rise isn't adding to your stress, this is a productive window.

   The science

   In animal tests GHRP-2 works at lower doses than Ipamorelin, though its maximal GH response wasn't higher (Raun 1998). A single dose raises cortisol about as much as a CRH stimulation test (Arvat 1997); there are no data on repeated use, so it's worth watching if you're stress-sensitive. In a 30-day continuous infusion in older adults, the GH response eased from about 3-fold to 1.8-fold but held (Bowers 2004); no study compares desensitization with GHRP-6 or Hexarelin.

   Sources

   • Raun et al. (1998)
   • Arvat et al. (1997)
   • Bowers et al. (2004)

   Updated Sep 2026

3. Any dayClinical

   What GHRP-2 is built on

   GHRP-2 has Phase II clinical data and is approved in Japan (as Pralmorelin) only as a diagnostic test for GH deficiency, never as a treatment. Users place it in the middle of the secretagogue spectrum: stronger than Ipamorelin, less hungry than GHRP-6, and fading less than Hexarelin.

   The science

   Developed by Bowers et al. as a second-generation growth hormone releasing peptide. Japanese regulatory approval for diagnostic use. The ghrelin receptor agonism is well-characterized — GHRP-2 is often used as a research reference compound for GHS-R1a pharmacology. Human studies are small: acute hormone responses (Arvat 1997), a 30-day infusion in older adults (Bowers 2004) and appetite (Laferrere 2005). FDA lists it in compounding category 2, citing a possible risk of immune reactions and serious adverse event reports, including increased insulin requirements.

   Sources

   • Bowers et al. (2004)
   • Arvat et al. (1997)

   Updated Sep 2026

Swipe for more ›

Mixing and a typical run.

Safety.

Goes with.

• CJC-1295 no DAC
• Sermorelin

Questions people ask.

Research.

Reference.

Cadence

2–3× daily

2–3x daily

Half-life

~30 min

Research basis

●●● Moderate

Animal studies + some human data